NeoGenomics Reports Strong 2025 Revenue Growth, Positive 2026 Guidance, and Strategic Product Launch

summarizeSummary

NeoGenomics reported strong double-digit revenue growth for Q4 and full-year 2025, alongside positive 2026 guidance projecting significant reductions in net loss and continued Adjusted EBITDA growth, bolstered by strategic product launches and patent resolution.

check_boxKey Events

• Strong Q4 and Full-Year 2025 Revenue Growth

  Consolidated revenue increased 11% in Q4 to $190 million and 10% for the full year to $727 million, driven by clinical volumes and higher-value tests.

• Improved Profitability Metrics

  Q4 net loss decreased 36% to $10 million, and full-year adjusted EBITDA grew 9% to $43 million, indicating an improving trend in operational profitability.

• Positive 2026 Financial Guidance

  The company projects 9-10% revenue growth, a 42-54% reduction in net loss, and 27-31% growth in Adjusted EBITDA for fiscal year 2026.

• Strategic Progress with New Product Launch

  NeoGenomics successfully resolved RaDaR ST patent litigation and anticipates the imminent clinical launch of its RaDaR ST MRD assay, targeting a significant molecular residual disease monitoring market.

auto_awesomeAnalysis

This 8-K provides the final Q4 and full-year 2025 financial results and crucial 2026 guidance, building on the preliminary revenue figures disclosed in January. The company demonstrated solid double-digit revenue growth in 2025, driven by clinical volumes and a shift towards higher-value tests like NGS. While the GAAP net loss increased for the full year, the fourth quarter showed a significant reduction in net loss, and the 2026 guidance projects a substantial improvement in profitability, with a projected 42-54% reduction in net loss and strong growth in Adjusted EBITDA. The successful resolution of patent litigation and the upcoming launch of the RaDaR ST MRD assay in a multi-billion dollar market further bolster the company's long-term growth prospects and strategic positioning. Investors should monitor the execution of the RaDaR ST launch and the company's progress towards its 2026 financial targets.